877149-05-8

Basic information

• Product Name: 4-bromo-2-methoxy-6-methylbenzonitrile
• Synonyms: 4-bromo-2-methoxy-6-methylbenzonitrile
• CAS NO: 877149-05-8
• Molecular Formula: C₉H₈BrNO
• Molecular Weight: 226.06992
• Mol File: 877149-05-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-bromo-2-methoxy-6-methylbenzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-2-methoxy-6-methylbenzonitrile(877149-05-8)
• EPA Substance Registry System: 4-bromo-2-methoxy-6-methylbenzonitrile(877149-05-8)

Safety Data

• Hazardous Substances Data: 877149-05-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
4-bromo-2-methoxy-6-methylbenzonitrile is used as a building block in organic synthesis for the creation of various pharmaceuticals and agrochemicals. Its unique structure and functional groups make it a valuable component in the development of new organic compounds.
Used in Pharmaceutical Research:
In pharmaceutical research, 4-bromo-2-methoxy-6-methylbenzonitrile is utilized as a reagent or precursor. Its role in the synthesis of pharmaceuticals aids in the discovery and development of new drugs, potentially contributing to advancements in medicine.
Used in Agrochemical Production:
4-bromo-2-methoxy-6-methylbenzonitrile is also used in the production of agrochemicals, where it serves as a key intermediate in the synthesis of compounds that can be used in agriculture to protect crops and enhance yields.

Upstream product

• 773837-37-9 sodium cyanide 
• 348169-39-1 4-bromo-2-methoxy-6-methyl-phenylamine 
• 50868-73-0 2-methoxy-6-methylbenzeneamine 
• 1181458-21-8 (4-Bromo-2-methoxy-6-methyl-phenyl)-amine hydrobromide 

Relevant articles and documents

N-((HETEROARYLMETHYL)-HETEROARYL-CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS

The present invention provides a selection of compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds.

Tetracycline compounds

The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.

SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS

Substituted 4-aminobenzamides, pharmaceutical compositions containing these compounds and also methods of using these compounds in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Synthesis and biological evaluation of 8-aminomethyltetracycline derivatives as novel antibacterial agents

The C-8 position of the tetracyclines has been largely underexplored because of limitations in traditional semisynthetic techniques. Employing a total synthetic approach allowed for modifications at the C-7 and C-8 positions, enabling the generation of structure-activity relationships for overcoming the two most common tetracycline bacterial-resistance mechanisms: ribosomal protection (tet(M)) and efflux (tet(A)). Ultimately, several compounds were identified with balanced activity against both Gram-positive and Gram-negative bacteria, including pathogens bearing both types of tetracycline-resistance mechanisms. Compounds were screened in a murine systemic infection model to rapidly identify compounds with oral bioavailability, leading to the discovery of several compounds that exhibited efficacy when administered orally in murine pyelonephritis and pneumonia models.

SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS

The invention relates to substituted 4-aminobenzamides, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

TETRACYCLINE ANALOGS

The present invention is directed to a compound represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.

POLYCYCLIC TETRACYCLINE COMPOUNDS

The present invention is directed to a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.

ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS

The present invention is directed to compounds of formula (I), wherein R1 is a ring and n is a number from 1 to 8. The invention also relates to use of the compounds in therapy as metabotropic glutamate receptor modulators, particularly in neurological and psychiatric disorders.